12,972 Shares in Kenvue Inc. (NYSE:KVUE) Bought by Quotient Wealth Partners LLC

Quotient Wealth Partners LLC bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,972 shares of the company’s stock, valued at approximately $236,000.

A number of other hedge funds and other institutional investors have also modified their holdings of KVUE. Manchester Capital Management LLC lifted its stake in Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after buying an additional 530 shares in the last quarter. Pacific Capital Wealth Advisors Inc. acquired a new stake in shares of Kenvue during the fourth quarter valued at approximately $28,000. Mather Group LLC. purchased a new stake in shares of Kenvue in the 1st quarter valued at approximately $28,000. Oakworth Capital Inc. acquired a new position in Kenvue in the 1st quarter worth approximately $31,000. Finally, Riverview Trust Co purchased a new position in Kenvue during the 1st quarter worth approximately $33,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Citigroup reduced their price objective on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. UBS Group lifted their target price on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Royal Bank of Canada restated an “outperform” rating and set a $24.00 price target on shares of Kenvue in a report on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $22.64.

Kenvue Stock Performance

KVUE stock opened at $21.82 on Friday. The company has a market capitalization of $41.78 billion, a price-to-earnings ratio of 27.97, a P/E/G ratio of 2.07 and a beta of 1.38. The firm has a 50 day moving average of $19.21 and a two-hundred day moving average of $19.48. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.10.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm had revenue of $4 billion during the quarter, compared to analysts’ expectations of $3.93 billion. During the same period in the prior year, the company posted $0.32 earnings per share. Kenvue’s revenue for the quarter was down .3% on a year-over-year basis. As a group, equities analysts anticipate that Kenvue Inc. will post 1.13 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.76%. This is an increase from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date is Wednesday, August 14th. Kenvue’s dividend payout ratio (DPR) is presently 105.13%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.